Corrado Girmenia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3949351/publications.pdf

Version: 2024-02-01

57719 62565 7,298 169 44 80 citations h-index g-index papers 172 172 172 6846 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients. Supportive Care in Cancer, 2022, 30, 4303-4314.	1.0	3
2	Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel. Critical Reviews in Oncology/Hematology, 2022, 172, 103623.	2.0	7
3	<scp>SARS oV</scp> â€⊋ vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey. American Journal of Hematology, 2022, 97, .	2.0	4
4	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. Bone Marrow Transplantation, 2022, 57, 949-958.	1.3	7
5	Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis. Hematological Oncology, 2021, 39, 20-26.	0.8	О
6	Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. American Journal of Transplantation, 2021, 21, 1622-1628.	2.6	35
7	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers, 2021, 13, 3240.	1.7	16
8	Sars-Cov-2 Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria: An Italian Multicenter Survey. Blood, 2021, 138, 2180-2180.	0.6	2
9	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. Hematological Oncology, 2020, 38, 189-196.	0.8	6
10	Isavuconazole therapy of disseminated and encephalic Saprochaete capitata infection in an acute myeloid leukemia patient treated with midostaurin Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020026.	0.5	5
11	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infection and Drug Resistance, 2020, Volume 13, 4697-4711.	1.1	21
12	Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clinical Transplantation, 2019, 33, e13666.	0.8	38
13	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 84-94.	2.8	35
14	<p>Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy</p> . Infection and Drug Resistance, 2019, Volume 12, 1127-1138.	1.1	14
15	Advances in <scp>CMV</scp> infection prevention and treatment after alloâ€ <scp>HSCT</scp> . Advances in Cell and Gene Therapy, 2019, 2, e53.	0.6	О
16	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Research and Treatment, 2019, 176, 483-494.	1,1	28
17	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leukemia Research, 2019, 81, 88-94.	0.4	11
18	Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. Medical Mycology, 2019, 57, S127-S137.	0.3	14

#	Article	IF	CITATIONS
19	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 16-25.	2.8	15
20	New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies. F1000Research, 2019, 8, 1202.	0.8	3
21	Reply to: Vaccination for hepatitis B virus in an Australian pre-biologic population with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 164.	0.4	O
22	ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2018, 73, 12-21.	1.3	91
23	Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplantation, 2018, 53, 1193-1197.	1.3	6
24	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection, 2018, 76, 20-37.	1.7	125
25	Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration?. Medical Mycology, 2018, 56, 263-278.	0.3	3
26	Estimated burden of fungal infections in Italy. Journal of Infection, 2018, 76, 103-106.	1.7	11
27	Isavuconazole: Case Report and Pharmacokinetic Considerations. Chemotherapy, 2018, 63, 253-256.	0.8	8
28	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. Journal of Antimicrobial Chemotherapy, 2018, 73, 3221-3230.	1.3	186
29	Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clinical and Experimental Rheumatology, 2018, 36, 317-328.	0.4	33
30	The predictive value of <i>Aspergillus </i> PCR testing on bronchoalveolar lavage fluid for early diagnosis of invasive pulmonary aspergillosis in hematologic patients. Leukemia and Lymphoma, 2017, 58, 2943-2946.	0.6	6
31	<i>Pneumocystis jirovecii</i> pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipientsâ€"authors' response. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw580.	1.3	13
32	Liposomal amphotericin B (AmBisome $\hat{A}^{@}$) at beginning of its third decade of clinical use. Journal of Chemotherapy, 2017, 29, 131-143.	0.7	26
33	An update on the safety and interactions of antifungal drugs in stem cell transplant recipients. Expert Opinion on Drug Safety, 2017, 16, 329-339.	1.0	18
34	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clinical Microbiology and Infection, 2017, 23, 935-940.	2.8	69
35	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	2.9	103
36	The start-up of the first hematopoietic stem cell transplantation center in the Iraqi Kurdistan: a capacity-building cooperative project by the Hiwa Cancer Hospital, Sulaymaniyah, and the Italian Agency for Development Cooperation Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017031.	0.5	11

3

#	Article	IF	Citations
37	EPIDEMIOLOGY OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE INFECTIONS IN MEDITERRANEAN COUNTRIES. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016032.	0.5	44
38	Pulmonary fungal infections in patients with acute myeloid leukaemia: is it the time to revise the radiological diagnostic criteria?. Mycoses, 2016, 59, 357-364.	1.8	7
39	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplantation, 2016, 51, 1032-1040.	1.3	26
40	The risk of infections in patients with myelodysplastic syndromes in 2016. Expert Review of Hematology, 2016, 9, 607-614.	1.0	13
41	ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2016, 71, 2386-2396.	1.3	226
42	ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2016, 71, 2397-2404.	1.3	211
43	Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration?. Medical Mycology, 2016, 54, 445-458.	0.3	6
44	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. Blood, 2016, 128, 5544-5544.	0.6	1
45	Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). Supportive Care in Cancer, 2015, 23, 3289-3295.	1.0	39
46	Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. Journal of Chemotherapy, 2015, 27, 1-12.	0.7	19
47	Antimicrobial Prophylaxis in Hematology. , 2015, , 275-296.		1
48	Acute promyelocytic leukemia in patients aged >70Âyears: the cure beyond the age. Annals of Hematology, 2015, 94, 195-200.	0.8	15
49	Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica, 2015, 100, e373-e376.	1.7	44
50	Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplantation, 2015, 50, 282-288.	1.3	142
51	EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014011.	0.5	10
52	Geotrichum. , 2014, , 88-93.		0
53	Epidemiology and risk factors for invasive fungal diseases in hematopoietic stem cell transplantation. Current Opinion in Hematology, 2014, 21, 459-465.	1.2	19
54	<i><scp>S</scp>trongyloides stercoralis</i> infection in allogeneic stem cell transplant: a case report and review of the literature. Transplant Infectious Disease, 2014, 16, 625-630.	0.7	15

#	Article	IF	CITATIONS
55	Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria. Journal of Hematology and Oncology, 2014, 7, 27.	6.9	16
56	Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 1080-1088.	2.0	54
57	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 872-880.	2.0	141
58	Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. Leukemia Research, 2014, 38, 469-474.	0.4	33
59	Cytomegalovirus in Bone Marrow Cells Correlates with Cytomegalovirus in Peripheral Blood Leukocytes. Journal of Clinical Microbiology, 2014, 52, 2183-2185.	1.8	4
60	Cross-recognition of aspergillus galactomannan caused by Listeria monocytogenes infection. Diagnostic Microbiology and Infectious Disease, 2013, 76, 250-251.	0.8	3
61	A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Hematological Oncology, 2013, 31, 117-126.	0.8	21
62	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica, 2013, 98, e127-e130.	1.7	99
63	The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?. Leukemia and Lymphoma, 2013, 54, 669-670.	0.6	1
64	Prospective Phase II Single-Center Study of the Safety of a Single Very High Dose of Liposomal Amphotericin B for Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia. Antimicrobial Agents and Chemotherapy, 2013, 57, 2596-2602.	1.4	27
65	Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. Journal of Antimicrobial Chemotherapy, 2013, 68, 2587-2591.	1.3	13
66	Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica, 2012, 97, 560-567.	1.7	61
67	Voriconazole in clinical practice. Journal of Chemotherapy, 2012, 24, 311-327.	0.7	49
68	Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clinical Microbiology and Infection, 2012, 18, 475-484.	2.8	227
69	New category of probable invasive pulmonary aspergillosis in haematological patients. Clinical Microbiology and Infection, 2012, 18, 990-996.	2.8	21
70	In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. International Journal of Antimicrobial Agents, 2012, 39, 440-443.	1.1	20
71	Safety and interactions of new antifungals in stem cell transplant recipients. Expert Opinion on Drug Safety, 2012, 11, 803-818.	1.0	14
72	The diagnostic role of galactomannan during antifungal prophylaxis. Comment on: "The role of antifungal treatment in hematology". Haematologica 2012;97(3):325-7. Haematologica, 2012, 97, e41-e41.	1.7	4

#	Article	IF	Citations
73	Trigeminal neuralgia as unusual isolated symptom of fungal paranasal sinusitis in patients with haematological malignancies. Neurological Sciences, 2012, 33, 647-652.	0.9	9
74	Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Annals of Hematology, 2012, 91, 309-310.	0.8	4
75	Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2012, 120, 4408-4408.	0.6	0
76	Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient. Journal of Clinical Virology, 2011, 52, 247-250.	1.6	5
77	Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients (reply). Haematologica, 2011, 96, e11-e11.	1.7	2
78	Enteral nutrition may cause false-positive results of Aspergillus Galactomannan assay in absence of gastrointestinal diseases. Mycoses, 2011, 54, e883-e884.	1.8	16
79	New-generation triazole antifungal drugs: review of the Phase II and III trials. Clinical Investigation, 2011, 1, 1577-1594.	0.0	14
80	LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011021.	0.5	20
81	Management of the 2009 A/H1N1 Influenza Pandemic in Patients with Hematologic Diseases: A Prospective Experience at an Italian Center. Acta Haematologica, 2011, 126, 1-7.	0.7	7
82	INVASIVE CANDIDA INFECTIONS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES AND HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: CURRENT EPIDEMIOLOGY AND THERAPEUTIC OPTIONS Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011013.	0.5	10
83	Prophylaxis of invasive fungal diseases in patients with hematologic disorders. Haematologica, 2010, 95, 1630-1632.	1.7	8
84	Clinically Driven Diagnostic Antifungal Approach in Neutropenic Patients: A Prospective Feasibility Study. Journal of Clinical Oncology, 2010, 28, 667-674.	0.8	81
85	Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed) Tj ETQq1 1 0.7 322-329.	84314 rg 0.7	BT /Overlock 79
86	Outpatient Parenteral Antibiotic Therapy in the Elderly: an Italian Observational Multicenter Study. Journal of Chemotherapy, 2009, 21, 193-198.	0.7	19
87	Molecular Identification and <i>In Vitro </i> Antifungal Susceptibilities of 28 Zygomycetes Isolates: FIMUA-ECMM Survey of Zygomycosis in Italy. Journal of Chemotherapy, 2009, 21, 363-364.	0.7	2
88	Prophylaxis and Treatment of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Results of a Consensus Process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clinical Infectious Diseases, 2009, 49, 1226-1236.	2.9	51
89	New generation azole antifungals in clinical investigation. Expert Opinion on Investigational Drugs, 2009, 18, 1279-1295.	1.9	87
90	Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients Blood, 2009, 114, 4545-4545.	0.6	0

#	Article	IF	Citations
91	Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?. European Journal of Haematology, 2008, 81, 242-243.	1.1	38
92	Galactomannan detection in Geotrichum capitatum invasive infections: report of 2 new cases and review of diagnostic options. Diagnostic Microbiology and Infectious Disease, 2008, 62, 450-452.	0.8	36
93	Improving outcomes of acute invasive Aspergillus rhinosinusitis n patients with hematologici malignancies or aplastic anemia: the role of voriconazole. Haematologica, 2008, 93, 159-160.	1.7	6
94	Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. Haematologica, 2008, 93, 104-110.	1.7	34
95	Outpatient Parenteral Antibiotic Therapy for Bone and Joint Infections: An Italian Multicenter Study. Journal of Chemotherapy, 2007, 19, 417-422.	0.7	50
96	Contamination by Cardboard Particles as a Cause of False-Positive Results for Aspergillus Galactomannan Enzyme Immunoassays. Vaccine Journal, 2007, 14, 929-929.	3.2	5
97	Fungal Infections in Recipients of Hematopoietic Stem Cell Transplants: Results of the SEIFEM B-2004 StudySorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clinical Infectious Diseases, 2007, 45, 1161-1170.	2.9	366
98	Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. Annals of Hematology, 2007, 86, 263-270.	0.8	21
99	A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. Leukemia and Lymphoma, 2006, 47, 1421-1423.	0.6	5
100	Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay Cross-Reactivity Caused by Invasive Geotrichum capitatum. Journal of Clinical Microbiology, 2006, 44, 3432-3434.	1.8	82
101	Candida guilliermondii Fungemia in Patients with Hematologic Malignancies. Journal of Clinical Microbiology, 2006, 44, 2458-2464.	1.8	64
102	The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica, 2006, 91, 1068-75.	1.7	650
103	Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. Clinical Microbiology and Infection, 2005, 11, 505-507.	2.8	37
104	Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies. Supportive Care in Cancer, 2005, 13, 987-992.	1.0	22
105	Genetic Variability among <i>Blastoschizomyces Capitatus</i> Isolates from Different Clinical Sources. International Journal of Immunopathology and Pharmacology, 2005, 18, 531-539.	1.0	4
106	Breakthrough Fusariosis in a Patient with Acute Lymphoblastic Leukemia Receiving Voriconazole Prophylaxis. Clinical Infectious Diseases, 2005, 40, 1212-1213.	2.9	37
107	Pulmonary Infections Complicating Hematological Disorders. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 445-457.	0.8	9
108	Breakthrough Candida krusei Fungemia during Fluconazole Prophylaxis followed by Breakthrough Zygomycosis during Caspofungin Therapy in a Patient with Severe Aplastic Anemia Who Underwent Stem Cell Transplantation. Journal of Clinical Microbiology, 2005, 43, 5395-5396.	1.8	26

#	Article	IF	CITATIONS
109	Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature. Journal of Clinical Microbiology, 2005, 43, 1818-1828.	1.8	347
110	Epidemiology of Fungal Infections in Hematological Malignancies in Italy: SEIFEM-2004 Study (Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne) Blood, 2005, 106, 4556-4556.	0.6	1
111	Lack of circulating Candida mannoprotein antigen in patients with focal hepatosplenic candidiasis. Journal of Medical Microbiology, 2004, 53, 103-106.	0.7	7
112	Aspergillus niger infection in patients with haematological diseases: a report of eight cases. Fallbericht. Aspergillus niger-Infektionen bei Patienten mit hamatologischen Erkrankungen. Mycoses, 2004, 47, 163-167.	1.8	25
113	Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. Leukemia, 2003, 17, 925-930.	3.3	38
114	Fluconazole in combination with flucytosine in the treatment of fluconazole-resistant Candida infections. Diagnostic Microbiology and Infectious Disease, 2003, 46, 227-231.	0.8	23
115	Comparison of the Susceptibilities of Candida spp. to Fluconazole and Voriconazole in a 4-Year Global Evaluation Using Disk Diffusion. Journal of Clinical Microbiology, 2003, 41, 5623-5632.	1.8	87
116	In Vitro Susceptibility Testing of Geotrichum capitatum: Comparison of the E-Test, Disk Diffusion, and Sensititre Colorimetric Methods with the NCCLS M27-A2 Broth Microdilution Reference Method. Antimicrobial Agents and Chemotherapy, 2003, 47, 3985-3988.	1.4	51
117	New antifungal drugs and new clinical trials. Current Opinion in Oncology, 2003, 15, 283-288.	1.1	11
118	Heterogeneity of Virulence-Related Properties in Listeria Monocytogenes Strains Isolated from Patients with Haematological Malignancies. International Journal of Immunopathology and Pharmacology, 2003, 16, 119-127.	1.0	8
119	Risk factors for nephrotoxicity associated with conventional amphotericin B therapy. American Journal of Medicine, 2002, 113, 351.	0.6	5
120	Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. British Journal of Haematology, 2002, 117, 379-386.	1.2	123
121	Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. Annals of Hematology, 2001, 80, 614-616.	0.8	16
122	Clinical significance of Aspergillus fungaemia in patients with haematological malignancies and invasive aspergillosis. British Journal of Haematology, 2001, 114, 93-98.	1.2	39
123	Nephrotoxicity of Amphotericin B Desoxycholate. Clinical Infectious Diseases, 2001, 33, 915-916.	2.9	21
124	Fluconazole and Candida krusei Fungemia. Archives of Internal Medicine, 2001, 161, 2267-2269.	4.3	8
125	HAART and Mycobacterium avium complex in an HIV infected patient with severe factor VII deficiency. Haemophilia, 2000, 6, 116-117.	1.0	1
126	Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. Leukemia, 2000, 14, 2052-2058.	3.3	8

#	Article	IF	CITATIONS
127	The epidemiology of fusariosis in patients with haematological diseases. British Journal of Haematology, 2000, 111, 272-276.	1.2	6
128	Treatment of long-lasting priapism in chronic myeloid leukemia at onset. Annals of Hematology, 2000, 79, 644-645.	0.8	24
129	Listeriosis in Recipients of Allogeneic Bone Marrow Transplants from Unrelated Donors. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 711-714.	1.3	11
130	Cutaneous Aspergillosis in Patients with Haematological Malignancies. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 362-365.	1.3	53
131	Deep Candida infections in the neutropenic and non-neutropenic host: an ISHAM symposium. Medical Mycology, 2000, 38, 199-204.	0.3	16
132	Detection of Cytomegalovirus Late (pp150) Antigen in Peripheral Blood Leukocytes of Patients with Human Immunodeficiency Virus–Related Lymphoma. Journal of Infectious Diseases, 2000, 182, 376-378.	1.9	0
133	The role of antimicrobial policies in neutropenic patients. International Journal of Antimicrobial Agents, 2000, 16, 303-307.	1.1	1
134	Making the diagnosis of fungal infection: when to start treatment. International Journal of Antimicrobial Agents, 2000, 16, 323-329.	1.1	7
135	The epidemiology of fusariosis in patients with haematological diseases. British Journal of Haematology, 2000, 111, 272-276.	1.2	59
136	Itraconazole Oral Solution as Prophylaxis for Fungal Infections in Neutropenic Patients with Hematologic Malignancies: A Randomized, Placebo ontrolled, Doubleâ€Blind, Multicenter Trial. Clinical Infectious Diseases, 1999, 28, 250-255.	2.9	233
137	Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. Leukemia, 1999, 13, 514-517.	3.3	17
138	Detection of Candida Mannoproteinemia in Patients with Neutropenic Enterocolitis. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 55-58.	1.3	21
139	Fluconazole and the Changing Epidemiology of Candidemia. Clinical Infectious Diseases, 1998, 27, 232-233.	2.9	24
140	Use of Voriconazole in Treatment of <i>Scedosporium apiospermum</i> Infection: Case Report. Journal of Clinical Microbiology, 1998, 36, 1436-1438.	1.8	116
141	Are we making progress in antifungal therapy?. Current Opinion in Oncology, 1997, 9, 314-320.	1.1	11
142	Management of infective complications in patients with advanced hematologic malignancies in home care. Leukemia, 1997, 11, 1807-1812.	3.3	26
143	Rising Incidence of Candida parapsilosis Fungemia in Patients with Hematologic Malignancies: Clinical Aspects, Predisposing Factors, and Differential Pathogenicity of the Causative Strains. Clinical Infectious Diseases, 1996, 23, 506-514.	2.9	173
144	Catheter-related cutaneous aspergillosis complicated by fungemia and fatal pulmonary infection in an HIV-positive patient with acute lymphocytic leukemia. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 524-526.	1.3	21

#	Article	lF	Citations
145	The Treatment of Candidemia. New England Journal of Medicine, 1995, 332, 1100-1102.	13.9	2
146	Biotype Diversity of Candida parapsilosis and Its Relationship to the Clinical Source and Experimental Pathogenicity. Journal of Infectious Diseases, 1995, 171, 967-975.	1.9	68
147	Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program. Antimicrobial Agents and Chemotherapy, 1994, 38, 2041-2046.	1.4	76
148	Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. European Journal of Clinical Microbiology and Infectious Diseases, 1994, 13, 797-804.	1.3	61
149	Clinical patterns of Fusarium infections in immunocompromised patients. Journal of Infection, 1994, 28, 7-15.	1.7	140
150	Late listeriosis after fludarabine plus prednisone treatment. British Journal of Haematology, 1994, 87, 407-408.	1.2	14
151	Detection of <i>Candida</i> in blood smears of patients with hematologic malignancies. European Journal of Haematology, 1994, 52, 124-125.	1.1	14
152	Diagnosis and treatment of invasive fungal infections in cancer patients. Supportive Care in Cancer, 1993, 1, 240-244.	1.0	7
153	Enterococcal septicemia in patients with hematological malignancies. European Journal of Clinical Microbiology and Infectious Diseases, 1993, 12, 241-247.	1.3	18
154	Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. European Journal of Clinical Microbiology and Infectious Diseases, 1993, 12, 1-8.	1.3	42
155	Fungemia in Patients with Leukemia. American Journal of the Medical Sciences, 1993, 306, 225-232.	0.4	78
156	Pneumonia in Allogeneic and Autologous Bone Marrow Recipients. Chest, 1993, 104, 371-375.	0.4	49
157	Spontaneous Pneumothorax in Patients with Leukemia: First Sign of Invasive Mycosis?. Annals of Internal Medicine, 1993, 118, 707.	2.0	3
158	Piperacillin plus Amikacin vs. Piperacillin plus Amikacin plus Teicoplanin for Empirical Treatment of Febrile Episodes in Neutropenic Patients Receiving Quinolone Prophylaxis. Clinical Infectious Diseases, 1992, 15, 290-294.	2.9	36
159	Gram-Positive Bacteremias in Neutropenic Patients. Leukemia and Lymphoma, 1992, 7, 104-105.	0.6	0
160	Onychomycosis As a Possible Origin of Disseminated Fusarium solani Infection in a Patient with Severe Aplastic Anemia. Clinical Infectious Diseases, 1992, 14, 1167-1167.	2.9	88
161	Single Daily Dose Ceftriaxone Plus Amikacin Treatment of Febrile Episodes in Neutropenic Patients Attending Day Hospital for Hematologic Malignancies. Oncology, 1992, 49, 49-52.	0.9	30
162	Fluconazole treatment ofBlastoschizomyces capitatus meningitis in an allogeneic bone marrow recipient. European Journal of Clinical Microbiology and Infectious Diseases, 1991, 10, 752-756.	1.3	37

#	Article	IF	CITATIONS
163	Spontaneous Pneumothorax Complicating Pulmonary Mycetoma in Patients with Acute Leukemia. Clinical Infectious Diseases, 1990, 12, 611-617.	2.9	35
164	Catheter-Related Right-Sided Endocarditis in Bone Marrow Transplant Recipients. Clinical Infectious Diseases, 1990, 12, 250-257.	2.9	75
165	Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients. Antimicrobial Agents and Chemotherapy, 1989, 33, 580-582.	1.4	67
166	Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer, 1989, 64, 2030-2034.	2.0	100
167	FATAL LISTERIA MENINGITIS IN IMMUNOSUPPRESSED PATIENT. Lancet, The, 1989, 333, 794.	6.3	2
168	Emergence of penicillin-resistant viridans streptococci causing septicemia in granulocytopenic patients. European Journal of Epidemiology, 1988, 4, 391-392.	2.5	10
169	Prevention and treatment of bacterial infections in hematopoietic cell transplants., 0,, 131-139.		O